Teva Announces Launch of Generic ACTOplus met in the United States

Teva Pharmaceutical Industries Ltd. TEVA announced today the launch of an authorized generic of ACTOplus met (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg. ACTOplus met is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met had annual sales of approximately $413 million in the United States, based on IMS sales data as of June 30, 2012.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsEvents
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!